Espumil™

LIPOPHILIC FOAM BASE

Espumil™ is an innovative, lipophilic foam base where the foam is generated by Fagron foam activating packaging. The unique delivery features of Espumil™ assure the simple application of lipophilic active pharmaceutical ingredients (APIs) and dermaceutical ingredients (DCIs) on difficult-to-treat areas, such as hairy skin and the scalp, without dripping. Espumil™ has proven to be an ideal and stable vehicle for the application of minoxidil. Espumil™ is designed according to the latest insights into topical vehicle safety and maximum solubility properties for lipophilic APIs and DCIs.

Benefits of Espumil™

  • Innovative base solution for easy compounding of foams
  • Creamy foam formulation with minimal greasiness
  • Light skin feel, drip-free
  • Gentle formulation without gaseous propellants; the foam is activated by Fagron’s foam dispenser
  • Compatible with lipophilic APIs and DCIs, such as minoxidil
  • Simple three-step compounding process
  • Especially suitable for application on difficult-to-treat areas, such as hairy skin and the scalp

No country selected

Please select a country from the dropdown to visit the webshop.

×

You are now being redirected to the Fagron shop.

Benefits of Espumil™

  • Innovative base solution for easy compounding of foams
  • Creamy foam formulation with minimal greasiness
  • Light skin feel, drip-free
  • Gentle formulation without gaseous propellants; the foam is activated by Fagron’s foam dispenser
  • Compatible with lipophilic APIs and DCIs, such as minoxidil
  • Simple three-step compounding process
  • Especially suitable for application on difficult-to-treat areas, such as hairy skin and the scalp

Product information

Technical data
Ingredients
Purified water, alcohol, humectant, acidifying agent, emulsifier, foaming agent, antioxidant
Appearance
Clear solution
Odor
Mostly odorless
pH
1.5-3.5
Shelf life unopened
36 months
Shelf life opened
12 months
Storage conditions
Store below 25°C
Download MSDS Download CoA
All ingredients have been generally recognised as safe by the USFDA, ANVISA and the Regulation (EC) No 1907/2006 (REACH) when used in accordance with their intended purposes.